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Abstract
Purpose—The purpose of this study was to assess the potential benefits and limitations of a
mixed beam therapy, which combined bolus electron conformal therapy (BECT) with intensity
modulated photon radiotherapy (IMRT) and volumetric modulated photon arc therapy (VMAT),
for left-sided post-mastectomy breast cancer patients.
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Methods—Mixed beam treatment plans were produced for nine post-mastectomy radiotherapy
(PMRT) patients previously treated at our clinic with VMAT alone. The mixed beam plans
consisted of 40 Gy to the chest wall area using BECT, 40 Gy to the supraclavicular area using
parallel opposed IMRT, and 10 Gy to the total planning target volume (PTV) by optimizing
VMAT on top of the BECT+IMRT dose distribution. The treatment plans were created in a
commercial treatment planning system (TPS), and all plans were evaluated based on PTV
coverage, dose homogeneity index (DHI), conformity index (CI), dose to organs at risk (OARs),
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normal tissue complication probability (NTCP), and secondary cancer complication probability
(SCCP). The standard VMAT alone planning technique was used as the reference for comparison.
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Results—Both techniques produced clinically acceptable PMRT plans but with a few significant
differences: VMAT showed significantly better CI (0.70 vs. 0.53, p < 0.001) and DHI (0.12 vs.
0.20, p < 0.001) over mixed beam therapy. For normal tissues, mixed beam therapy showed better
OAR sparing and significantly reduced NTCP for cardiac mortality (0.23% vs. 0.80%, p = 0.01)
and SCCP for contralateral breast (1.7% vs. 3.1% based on linear model, and 1.2% vs. 1.9% based
on linear-exponential model, p < 0.001 in both cases), but showed significantly higher mean (50.8
Gy vs. 49.3 Gy, p < 0.001) and maximum skin doses (59.7 Gy vs. 53.3 Gy, p < 0.001) compared
with VMAT. Patients with more tissue (minimum distance between the distal PTV surface and
lung approximately > 0.5 cm and volume of tissue between the distal PTV surface and heart or
lung approximately > 250 cm3) between distal PTV surface and lung may benefit the most from
mixed beam therapy.
Conclusion—This work has demonstrated that mixed beam therapy (BECT+IMRT : VMAT =
4 : 1) produces clinically acceptable plans having reduced OAR doses and risks of side effects
compared with VMAT. Even though VMAT alone produces more homogenous and conformal
dose distributions, mixed beam therapy remains as a viable option for treating post-mastectomy
patients, possibly leading to reduced normal tissue complications.
Keywords
Post-mastectomy radiotherapy; mixed beam therapy; bolus electron conformal therapy; intensity
modulated photon radiotherapy; volumetric modulated photon arc therapy
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1. INTRODUCTION
A mastectomy is highly recommended for patients with locally advanced primary breast
cancer and extensive lymph node involvement. Due to prevalence of microscopic disease
after mastectomy, post-mastectomy radiotherapy (PMRT) is commonly performed to
sterilize residual tumor cells; it has been shown to improve the overall survival for invasive
breast cancer patients by reducing the risk of tumor recurrence and cancer mortality.1 At our
institution, the standard of care for PMRT has been Helical Tomotherapy2, 3 or Volumetric
Modulated photon Arc Therapy (VMAT).4 Both modalities provide good target coverage
and dose homogeneity, but the large volume of stray radiation dose to normal tissues like
lung, heart, and contralateral breast is a concern because that can potentially cause
radiogenic side effects like radiation pneumonitis, cardiac toxicity, and secondary cancers.
5–8
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The inherent rapid distal dose fall-off of therapeutic electron beams makes them suitable for
treatment of the chest wall where the target volume is superficial and organs at risk (OARs)
like the lungs and heart underlie the target.9, 10 Advanced electron therapy technique uses
energy (range) modulation without and with intensity modulation to further control the distal
dose fall-off.11 One method of achieving energy (range) modulation for electron beams is
bolus electron conformal therapy (BECT).12 It uses a variable thickness wax bolus on the
patient surface, where the distal surface is machined to achieve an excellent fit to the
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patient’s chest wall, and the proximal surface is machined to conform the 90% dose surface
to the planning target volume (PTV) while sparing distal OARs.11, 13 BECT has been shown
to be very effective at treating post-mastectomy patients,13–15 but dose homogeneity can
sometimes be a problem. 13, 16 The feasibility of optimizing intensity modulated photon
radiotherapy (IMRT) over a BECT dose plan to improve PTV dose homogeneity has been
experimentally demonstrated using a phantom for simulated chest wall and parotid cases,17
but has not been evaluated for real patients’ treatment planning.
The purpose of this planning study was to investigate the potential benefits and limitations of
BECT mixed with IMRT and VMAT beams for left-sided post-mastectomy breast cancer
patients by comparing this mixed beam therapy with the standard VMAT planning technique
used in our clinic.4
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2. METHODS AND MATERIALS
2.A. Patient selection
This study retrospectively included nine left-sided post-mastectomy patients. All patients
received a modified radical mastectomy and were treated by a single radiation oncologist at
our institution. Computed tomography (CT) scans had been acquired on a large bore GE
LightSpeed 16 CT scanner (General Electric Medical Systems, Little Chalfont, United
Kingdom), and all patients had been scanned in the supine position with the free breathing
CT data sets including anatomy from the top of head to lower abdomen with a slice
thickness of 0.25 cm. All CT data sets were anonymized and assigned a unique research
identifier, CW1 to CW9 (Table I). Treatment planning for all modalities was performed in a
commercially available TPS (Pinnacle3 v9.8, Philips Medical Systems, Fitchburg, WI).
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2.B. Contours
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The PTV for each patient, which had been previously contoured by the same radiation
oncologist at our institution based on consensus definitions from RTOG breast cancer Atlas,
included the chest wall, supraclavicular area, and internal mammary chain (IMC) area.
Contouring the chest wall targets on CT was aided by placing radiopaque marker at the time
of CT simulation for identification of the mastectomy scar and the area of the chest wall,
which in the radiation oncologist’s judgment was at risk for recurrence and should be
included in the prescription dose. As for the supraclavicular area, the upper border was
below the level of the cricoid, the medial border was at the vertebral pedicles and lateral
border consisted of the portion of the axilla that remained undissected, and the inferior
border extended to the caudal aspect of the clavicular head. The IMC area included the
internal mammary vessels in the first three intercostal spaces. The patients had a 1-cm thick
Superflab bolus (Superflab Bolus, Radiation Products Design, Inc., Albertville, MN) placed
on the surface of their ipsilateral chest wall for the purpose of dose buildup.3, 4, 18
Figure 1 illustrates the contours used in the treatment planning for patient CW1. The green
plus red is the original PTV contour created by the radiation oncologist. The red contour is
the modified “PTV evaluation” that does not include the 1-cm tissue-equivalent bolus
because the dose within the thermoplastic bolus was unnecessary for this study. This contour
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was used in planning and optimizing all VMAT techniques and for evaluating the PTV dose
metrics for all techniques; its volume is shown in Table I for each patient. The yellow
contour is a 5-mm shell that is used to estimate skin dose within the PTV. The red double
arrow along the central axis of electron beam represents the distance between the distal PTV
surface and lung (dPTV-Lung), which is shown in Table I for each patient. The volume of
tissue between the distal PTV surface and heart or lung (VPTV-heart/Lung) is also shown in
Table I for each patient.
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Figure 2 shows a three-dimensional (3D) rendering of the three defined PTVs used in
planning and evaluating all techniques in this study together with their dose prescriptions.
The image on the left shows the supraclavicular PTV and BECT PTV for mixed beam
therapy. The border separating the two PTVs was chosen where the lowest available electron
energy that covered most of the BECT PTV but was insufficiently energetic to cover the
thick, superior part of it. The border was always selected above the patient’s heart and as
superior as possible to reduce the radiation to the heart. The image on the right shows the
composite PTV used for the standard VMAT plan and the VMAT component of the
composite mixed beam plan; it was also used as the evaluation PTV for all techniques.
Organs at risk (OARs), contoured by the radiation oncologist for all the patients, included
lungs, whole heart, contralateral breast, esophagus, trachea, and spinal cord. Additional
contours that were added included: (1) a 0.8-cm thick ring around the PTV used to control
hot or cold spots around the PTV, (2) an external skin contour used in the mixed beam
planning, (3) a 0.5-cm thick shell for evaluating the skin dose inside the PTV, and (4)
unspecified tissue which included everything inside the external skin contour excluding the
above mentioned OARs.
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2.C. VMAT treatment planning
VMAT plans were created for an Elekta Versa HD™ radiotherapy system (Elekta, Crawley,
United Kingdom) using 6 MV photons, 0° couch angle, and 45° collimator angle. The dose
prescription was 50 Gy administered in 25 fractions, and the dose calculations were
conducted using a dose grid resolution of 0.4 cm3. Each plan utilized two partial arcs due to
the complexity of the cases and close proximity to lungs, heart, and contralateral breast.
Each arc covered approximately 220° with about 56 control points (4° gantry spacing). The
first arc was planned to be delivered counterclockwise with starting angles between 170° and
180° (floor to ceiling) and stopping angles between 304° and 320°. The second arc was
planned to be delivered clockwise over the same arc. Inverse planning for all VMAT
techniques was done using the SmartArc optimization algorithm utilized by Pinnacle TPS.
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The VMAT plans were optimized using a four-run technique. The first run consisted of 75
iterations of the SmartArc algorithm in addition to 25 iterations of the convolution dose
algorithm with the primary focus on PTV coverage. All PTV optimization objectives were
set to a weight of 100. The starting optimization objectives and constraints for all VMAT
plans are shown in Table II. All subsequent runs consisted of 35 iterations each of the
SmartArc algorithm. For the second run the hotspots from the first run were contoured, and
an objective was added with maximum dose constraint set to 52 Gy with a weight of 100.
The hot spots were contoured by creating a contour from the 53.5 Gy isodose line. For the
Med Phys. Author manuscript; available in PMC 2019 July 01.
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third run the “PTV evaluation” region of interest (ROI) was uniformly contracted by 0.2 cm
and labeled PTV min dose. This ROI was added to the optimizer and given a minimum dose
objective of 50 Gy with a weight of 100. In addition, hotspots from the second run were
contoured, and an objective was added with maximum dose constraint set to 52 Gy with a
weight of 100. The fourth run focused on reducing the dose to the heart, total lung (both left
and right lungs), and contralateral breast. At the beginning of the run the target doses were
reduced by an amount that resulted in the objective value for that ROI to be around 0.005.
The objectives can be adjusted in real time as the optimizer is running. While the last run
was being optimized the target doses of the aforementioned ROIs were adjusted to keep their
objective value around 0.005.
2.D. Mixed beam treatment planning
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The mixed beam treatment planning was a multiple modality technique utilizing electrons,
IMRT photon beams, and a dual-arc VMAT. It used a 4:1 ratio where 20 of the 25 total
fractions consisted of an electron field to the chest wall (including internal mammary chain
and axillary lymph nodes) and parallel opposed IMRT photon beams to the superior chest
wall and supraclavicular volume. Generalizations of these two PTVs are shown in the left
image of Fig. 2. The final 5 of the 25 total fractions utilized a dual-arc VMAT technique,
which was optimized on top of the dose distribution from the first 20 fractions. The VMAT
PTV for this technique, as well as the PTV used for final plan evaluation, is shown in the
right image of Fig. 2. The prescription doses of the electron and IMRT photon fields were 40
Gy in 20 fractions, and the dual-arc VMAT was prescribed to a composite 50 Gy in 5
additional fractions.
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For BECT planning, the 1-cm Superflab bolus that was in place in the original CT images
was removed by contouring it and overriding its density to that for air (0.001 gcm−3),
because it was replaced with a 3D conformal electron bolus for the electron portion of this
technique. Electron isocenter was placed on the central slice of the BECT PTV, 5 cm
anterior to the patient surface, resulting in a pre-bolus SSD of 105 cm, which allowed for
adequate electron applicator clearance. The electron isocenter was also located laterally from
the BECT PTV patient midline edge to approximately place the point in the center of the
BECT PTV. The gantry angle (approximately 45°) was chosen so the beam direction was
approximately perpendicular to the patient surface on central axis (cf Fig. 3). For each
patient the lowest available electron energy that gave adequate coverage of the BECT PTV
using a single electron beam was selected. The goal of having the 90% dose surface
circumscribe the distal surface of the BECT PTV required energies of 11, 13 and 16 MeV
with R90 values of 3.5, 4.0 and 5.0 cm, respectively (cf Table 1).
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The electron field shape was created to conform its perimeter to the beams-eye-view (BEV)
of the BECT PTV plus a 1-cm margin, which ensured the PTV was inside the penumbra and
should receive 90% of the given dose. The couch was rotated so the beam at the superior
border had a straight edge. The superior field edge matched the superior border of the
“BECT PTV” to reduce the penumbra from spilling into the supraclavicular PTV. The
collimator was adjusted so the medial jaw was parallel to the BECT PTV medial edge. This
adjustment maximized the distance between the BECT PTV outer edge and the electron
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field’s (cutout) outer edge. The smallest electron applicator that contained the field shape
was selected, being either 20×20 cm2 or 25×25 cm2.
The dose for the electron beam without bolus was calculated in Pinnacle using the pencil
beam algorithm (PBA)19, 20 with a dose grid resolution of 0.2 cm3. The plan’s finalized ROI
structures and electron beam characteristics were exported from the TPS and transferred to
the .decimal p.d BolusECT® software (v5.1.9) (.decimal LLC, Sanford, FL) for bolus
design.
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Bolus design began by entering the beam energy for the BECT PTV and external skin ROI
structures. The bolus was designed using a series of bolus operators, typically including
creation operator, isodose shift operator, smoothing operator, truncation operator, and
specified shift operator, based on those of Low et al 12 that resulted in the most conformal
coverage of the distal surface of the BECT PTV by the 90% dose surface. The .decimal p.d
BolusECT® software calculated dose using the pencil beam redifinition algorithm (PBRA).
21–24

Once the bolus design was finalized, the digital bolus contour was transferred as a structure
back into a copy of the original treatment plan in the Pinnacle TPS. The density of the bolus
structure was set to 0.92 gcm−3 according to Low and Hogstrom.25 The dose distributions
relative to given dose were calculated using the PBA in the Pinnacle TPS. Monitor Units
(MUs) were calculated to deliver the prescribed dose (40 Gy) to 95% of the given dose.
Dose per monitor unit for the beam, which depended on beam energy, applicator size, field
size, and SSD to the bolus surface along central axis, was calculated according to Hogstrom
et al.26
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Continuing the planning process, the parallel opposed 6 MV IMRT photon fields based on
the Elekta Versa HD™ radiotherapy system were delivered to the supraclavicular PTV. The
isocenter was placed on the inferior, medial border of the supraclavicular PTV. The gantry
beam angles, chosen to reduce dose to the esophagus and trachea, were approximately 345°
and 165°. The couch angle and collimator angle were 0°. The IMRT beams were optimized
to deliver 40 Gy to supraclavicular PTV and limit dose to OARs using the direct machine
parameter optimization (DMPO) optimization algorithm and a dose grid resolution of 0.4
cm3 in Pinnacle TPS.
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After the BECT PTV and supraclavicular PTV were covered by their 40 Gy prescription, the
VMAT component of the plan was determined using the VMAT planning technique identical
to that described previously with the exception it was optimized on top of the initial mixed
beam dose distributions. The purpose of the 10 Gy VMAT component was to reduce dose
heterogeneities in the mixed beam plan due to the irregular bolus surface,16, 17 the abutting
electron and photon beams, and the parallel opposed photon beams in the supraclavicular
region.
2.E. Plan evaluation
For each treatment plan, the following three criteria were required to be met to be considered
clinically acceptable and representative of those plans administered to our patients: (1) the
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fraction of the PTV receiving at least 95% of the prescribed dose is greater than or equal to
95% (V95 ≥ 95%); (2) the volume of total lung receiving greater than 20 Gy is less than 20%
(V20 < 20%), as this has been shown to be the clinical threshold for pneumonitis27, 28; and
(3) the volume of heart receiving greater than 22.5 Gy is less than 20% (V22.5 < 20%), as a
dose of 22.5 Gy to the heart has been correlated to increased rates of reduced myocardial
perfusion.29
In addition, the volume of lung receiving at least 5 Gy should be less than or equal to 42%
(V5 ≤ 42%), as any more is related to an increase in lung toxicity.30 The mean heart dose
should be less than 5 Gy (Dmean < 5 Gy), and doses to the heart above 30 Gy have also been
shown to increase cardiac mortality and should be minimized.31
Among the dosimetric evaluation metrics, the dose homogeneity index (DHI) is defined as:

Author Manuscript

DHI =

Dmax − Dmin
DRx

,

where Dmax is the dose to 2% of the PTV, Dmin is the dose to 98% of the PTV, and DRX is
the prescription dose.32 A DHI value of zero is ideal and represents a homogenous dose to
the entire PTV. The conformity index (CI) is defined as

CI =

TV RI
TV

×

TV RI
V RI

,

Author Manuscript

where TVRI is the target volume receiving the reference dose (47.5 Gy), TV is the PTV, and
VRI is the volume receiving reference isodose of 47.5 Gy.33 A CI value of unity means the
reference dose volume conformed exactly to the target volume.
The Lyman-Kutcher-Burman (LKB) probit model 34–36 was used to calculate the normal
tissue complication probability (NTCP) for the lungs with radiation pneumonitis grade two
or higher as an endpoint:
NTCP =

t −t2 /2
1
e
dt
2π −∞

∫

t = (D − D50(V))/(m · D50(V))
D50(V) = D50 /V n

Author Manuscript

where D50(V) is the tolerance dose that would result in a 50% complication probability for
the partial volume V, D50 is the tolerance dose that would result in a 50% complication
probability for the full organ, n indicates the volume effect, and m is inversely proportional
to the slope of the dose-response curve. D50 = 30.8 Gy, n = 0.99, and m = 0.3736 were used
in this study.
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NTCP for radiation-induced cardiac mortality was computed for the heart using the relative
seriality model: 37

NTCP = 1 −

n

∏

V i /V 1/s
s
[1 − P(Di) ]

i=1
−exp{eγ(1 − D/D50)}

P(D) = 2

Author Manuscript

where γ is the maximum relative slope of the dose-response curve and D50 is the dose that
will result in a 50% probability of a complication, s is the relative seriality that describes the
hybrid serial/parallel architecture of the organ, n is the number of voxels in the dosecalculation volume, Di is the dose in each subvolume, Vi is the volume of each subvolume in
the differential dose-volume histogram, and V is the total volume of the organ. D50 = 52.3
Gy, s = 1.0, and γ = 1.2838 were used in this study.
Secondary cancer complication probabilities (SCCP) were calculated using the product of
the linear organ equivalent dose (OEDorg) and the organ specific absolute cancer incidence
rate in percent per gray (Inorg).39 OEDorg was calculated using the linear non-threshold
(LNT) and linear exponential (LEXP) models, i.e.
1
∑ (vi · Di),
org = V
org i

OED

Author Manuscript

−αDi
1
OEDorg, linear − exp =
(vi · Di · e
),
∑
V org
i

where vi is the volume receiving dose Di and is summed over all voxels of the organ of
volume Vorg, α is the organ specific cell sterilization parameter. SCCP was calculated for the
lungs where Inorg= 1.68% Gy−1 and α = 0.085 Gy−1, and for the contralateral breast where
Inorg= 0.78% Gy−1 and α = 0.085 Gy−1.40
2.F. Statistical Analysis
The paired two-sided t-test was used to determine the statistical significance of the
differences. The analyses were conducted with R software (version 3.2.3, R Foundation),
and the differences were considered significant when p < 0.05.
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3. RESULTS
Table III shows CI, DHI for PTV and NTCP, SCCP values for OARs for each PMRT patient.
Figure 3 and 4 show the dose distributions for two (CW2 and CW6) PMRT patients’ mixed
beam plans with and without VMAT component. These two patients were chosen as patients
who, based on normal tissue sparing, benefited the most (CW2) and the least (CW6) from
mixed beam therapy. For plans without VMAT component, the prescription dose was
changed from 40 Gy to 50 Gy for the BECT and supraclavicular IMRT fields to make them
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clinically comparable. Consistent with previous study,17 the mixed beam reduced the hot
spots within and outside the target at the expense of increased low dose outside PTV.
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Figures 5, 6 and 7 show the dose distributions and dose volume histograms (DVHs) for
patients CW2 and CW6 from mixed beam therapy. Compared to VMAT plans, the mixed
beam plans shrink the medium and low dose volumes within the normal tissues especially
for CW2, while showing greater dose spread (e.g., hotspots) within the PTV. This is most
apparent in the lateral portion of the PTV at the beam abutment region of the electron field
and the supraclavicular IMRT fields. In addition, any region of the machineable wax bolus
that has a steep or sharp edge causes underlying dose heterogeneities in the patient.
Smoothing the machineable wax bolus reduced some of the dose heterogeneities, but not all
could be removed because of bolus surface following the curvature of chest wall. Mixing
VMAT with BECT+IMRT (1:4) reduced, but did not eliminate dose heterogeneities, as was
the case reported previously.17
The mean PTV evaluation metrics are summarized in Table IV. All of the mixed beam and
VMAT treatment plans were deemed clinically acceptable by the radiation oncologist. Due
to the hotspots in the mixed beam plans, the maximum dose to the PTV and the PTV volume
receiving 107% of the prescription dose were significantly higher than VMAT plans. The
VMAT plans also showed better conformity and homogeneity than the mixed beam plans.

Author Manuscript
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The mean OAR evaluation metrics are also summarized in Table IV. All plans met the
acceptance criteria that V20 < 20% for the lungs and V22.5 < 20% for the heart. Mixed beam
therapy showed an average reduction in volume of lungs receiving at least 5 Gy of nearly
10% compared to VMAT; however, the high dose region of lungs was slightly greater for
mixed beam therapy compared to VMAT, but still under the 20% requirement of the plan
acceptance criteria. Mixed beam therapy did not significantly change NTCP for radiogenic
pneumonitis or SCCP for secondary lung cancer based on LNT model from those using
VMAT, but it significantly reduced SCCP based on LEXP model. The volume of heart
receiving at least 5 Gy was significantly lower, over 20%, for mixed beam therapy compared
to VMAT. Also the volume of heart receiving at least 22.5 Gy or 30 Gy was significantly
decreased for mixed beam therapy. These great differences in dose metrics were reflected in
statistically significant reduction of NTCP for cardiac mortality over VMAT. The mean
contralateral breast dose, the volume of contralateral breast receiving at least 5 Gy, and
SCCP were statistically significantly reduced for mixed bean therapy. Mean dose to the skin
(5 mm shell) was statistically significantly higher (50.8 Gy) and just over prescription dose
(50 Gy) for mixed beam therapy and was slightly lower (49.3 Gy) than the prescription dose
for VMAT. Mixed beam therapy also showed 12% higher maximum skin dose (59.7 Gy vs.
53.3 Gy).

4. DISCUSSION
This study compared a mixed beam therapy with a well-defined VMAT used at our institute
for post-mastectomy breast cancer patients. Both techniques provided good coverage of the
target, while mixed beam therapy showed, with statistical significance, less conformity and
less dose homogeneity compared to standard VMAT. The mixed beam’s inclusion of 25%
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VMAT significantly reduced the dose heterogeneities within the target. Our technique
significantly reduced the portion of the target volume receiving greater than 110% of the
prescription dose (PTV110), being 3.9 ± 2.7%, as compared to 15.1 ± 5.8% from a study by
Opp et al14 that evaluated BECT alone for 21 left-sided PMRT patients. Although their PTV
did not include regional nodal area, this significant reduction still indicated the improvement
of dose homogeneity and the benefit of adding VMAT component to BECT.
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Our mixed beam technique reduced low doses but increased high doses to the lungs as
compared to VMAT. This is apparently due to dose spilling of the electron beam to the
ipsilateral lung. However, since the electron beam dose falls off quickly in the low dose area,
the contralateral lung has reduced dose. Dmean, V̄ 5 and V̄20 for the lungs in our mixed beam
study are lower than those in one study by van der Laan et al9 that evaluated a combined
conformal electron and photon IMRT planning technique for 10 left-sided PMRT patients.
Dmean for the lungs from our mixed beam therapy is comparable to that in Opp et al.14
Dmean for the heart from our mixed beam therapy is comparable to that in Opp et al,14 while
Dmean, V̄5 and V̄30 for the heart in our mixed beam study are lower than those in van der
Lann et al.9 Cardiac toxicity is a serious concern for women undergoing PMRT and has been
indicated as a primary reason for mortality among breast cancer survivors.41–44 This work
has shown with statistical significance that our mixed beam therapy applied to left-sided
PMRT patients can reduce NTCP for cardiac mortality from 0.8% with VMAT to 0.2%.
Hence, patients with prior or current cardiopulmonary complications or those at an increased
risk of cardiovascular disease45 might benefit from our mixed beam therapy technique.
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Dmean for the contralateral breast in our mixed beam study is comparable to that in Opp et
al,14 while Dmean and V̄5 for the contralateral breast in our study are higher than those in van
der Lann et al.9 It was also determined that our mixed beam therapy can significantly reduce
SCCP for the contralateral breast from 3.1% with VMAT to 1.7% based on LNT model, and
from 1.9% with VMAT to 1.2% based on LEXP model. This is especially important for
younger patients. Studies have determined that premenopausal women under the age of 40 –
45 years old are at the highest risk for second cancers of the contralateral breast after
radiation exposure and women over that age shown little or no risk of radiation-induced
breast cancer46, 47. It is possible that younger patients requiring PMRT may further benefit
from mixed beam therapy.
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Skin erythema is expected for post-mastectomy chest wall patients since the skin is included
in the PTV. Dose to the skin should be as close to prescription dose (50 Gy) as possible to
sterilize any microscopic disease still present. The mean skin dose from our mixed beam
therapy was only slightly higher than VMAT (50.8 vs. 49.3 Gy), although the maximum
dose was much higher (59.7 vs. 53.3 Gy). However, for all the mixed beam plans in this
study, the volume of skin that has dose greater than 55 Gy does not exceed 8 cm3 (~16 cm2
in terms of area) and the average volume is 3.7 cm3 (~7.4 cm2 in terms of area), which is not
clinically significant. According to Hall and Giaccia48, the combination of total dose (50
Gy) and time (35 days) of our treatment may cause moist or dry desquamation of skin, and
those usually can be managed. Patients who were treated with electron bolus were able to
complete treatment without interruption: Perkins et al.13 studied two PMRTs patient who
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underwent BECT technique and found the patients had brisk erythema and moist
desquamation but were able to complete treatment without interruption. Patient discomfort
caused by skin reaction was not severe and was managed with healing occurring within 2
weeks of treatment completion; Kim et al.15 used BECT to treat a PMRT patient with
recurrent inflammatory breast cancer and reported the patient developed grade 2 erythema
and hyperpigmentation in the treatment area that did not cause desquamation. The patient
developed erythematous and maculopapular rash six months after the treatment, which was
consistent with the inflammatory effects of radiation treatment. Those patients were treated
with electron bolus alone without IMRT or VMAT mixture, which means the skin doses
were even higher than those in our study.

Author Manuscript

Based on Tables I and III, this work has suggested that patients like CW4 or CW2 with
thicker minimum dPTV-Lung and/or larger volume of tissue between the distal PTV surface
and heart or lung (VPTV-heart/Lung) might benefit the most from mixed beam therapy, while
patients like CW6 with a thin layer of intervening tissue could not receive the same dose
sparing. Some tissue distal to the PTV (approximately, minimum dPTV-Lung > 0.5 cm and
VPTV-heart/Lung > 250 cm3) is needed to attenuate the electrons before entering the lung
tissue even with the use of the wax bolus, and the thicker tissue has increased ability to stop
more of the electron beam leading to decreased dose to the heart and lungs. In addition it
would be advantageous to pay closer attention to the BECT PTV thickness in the lateral and
posterior areas. When this region of the PTV is very thick the required electron energy may
need be increased to achieve adequate target coverage, but the final choice of electron
energy is still limited by the minimum dPTV-Lung because the high energy electrons will
easily penetrate the chest wall and enter the lung tissue if the chest wall is very thin.

Author Manuscript

Because VMAT was the standard of care for PMRT in our institute at the time of this study,
we opted to compare our mixed beam therapy with VMAT instead of conventional tangential
therapy which is current standard of care for PMRT in the US. However, according to
literature49, 50 and our previous experience, tangential PMRT could introduce large dose
heterogeneities in the PTV and can induce suboptimal cosmesis after treatment. In addition,
tangential PMRT would introduce higher heart dose and slightly lower lung dose than bolus
electron conformal therapy without mixing with IMRT14, and would introduce higher lung,
heart and coronary artery doses than VMAT.51, 52

Author Manuscript

Potential future work for this study could be adding intensity modulated electron therapy
(IMET)16 for the chest wall into the study. This technique could potentially reduce dose
spread and the magnitude of hot spots and reduce skin complications, which could remove
the need for the VMAT component of our mixed beam. IMET could therefore potentially
lead to more conformal and homogenous dose distributions to the PTV than the current
mixed beam technique, reducing the low dose bath to OARs. In addition, it would be
interesting to study breath control for our mixed beam technique. Deep inspiration breath
hold has been shown to significantly reduce mean heart and left anterior descending artery
(LAD) dose in patients receiving breast-conserving radiotherapy or PMRT using photon
techniques53–60, which translates to further reduction of risk of heart disease. However, this
may not be the case for the single electron field (approximately perpendicular to the chest
wall) used in our study and the low-density lung tissue may not be able to attenuate the
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electron beam sufficiently although the distance between PTV and heart has been increased.
Further study is required to confirm the benefit of breath hold for our mixed beam therapy.

5. CONCLUSION

Author Manuscript

The results of this study have effectively shown that our mixed beam therapy technique
might be advantageous to VMAT particularly for specific patients. Even though VMAT
produces more homogenous and conformal dose distribution to the PTV, the dose coverage
of mixed beam therapy was sufficient for it to be a viable option for treating postmastectomy patients. Contrastingly, mixed beam therapy can significantly lower the dose to
the heart and contralateral breast. The former makes it potentially beneficial for the patients
with prior or current cardiopulmonary complications or those at an increased risk of
cardiovascular disease, the latter makes it potentially beneficial for young women with an
increased risk of radiation-induced cancer of the contralateral breast. In line with the benefits
of personalized medicine, patients with more tissue between the distal PTV surface and lung
might benefit the most from our mixed beam therapy technique.
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FIG. 1.
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Planning target volume (red) of a typical PMRT patient for mixed beam therapy and VMAT,
1 cm tissue-equivalent bolus (green), and 5 mm skin contour (yellow). The white dashed line
represents the central axis of electron beam, and the red double arrow represents the PTVlung distance along the central axis (dPTV-Lung).
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FIG. 2.

Planning target volumes (PTV) with prescriptions for mixed beam therapy and VMAT.
(Left) BECT PTV (red) and supraclavicular PTV (yellow) for mixed beam therapy; (Right)
the same green area used as VMAT PTV, VMAT component of mixed beam therapy PTV
and evaluation PTV.
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FIG. 3.

Axial view of dose distribution for mixed beam plans in the BECT area (a, d), in the
supraclavicular area (b, e), and sagittal view of dose distribution (c, f) for patient CW2 (the
best case). The left column (a, b, c) and right column (d, e, f) show the doses for plans
without and with VMAT component, respectively. The orange color wash contour represents
the PTV, the dark blue color wash represents the electron bolus.
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FIG. 4.

Axial view of dose distribution for mixed beam plans in the BECT area (a, d), in the
supraclavicular area (b, e), and sagittal view of dose distribution (c, f) for patient CW6 (the
worst case). The left column (a, b, c) and right column (d, e, f) show the doses for plans
without and with VMAT component, respectively. The orange color wash contour represents
the PTV, the dark blue color wash represents the electron bolus.
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FIG. 5.

Axial and sagittal views of isodose distribution for VMAT (upper) and mixed beam plans
(lower) for patient CW2 (the best case). The orange color wash contour represents the PTV,
the dark blue color wash represents the electron bolus.
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FIG. 6.

Axial and sagittal views of isodose distribution for VMAT (upper) and mixed beam plans
(lower) for patient CW6 (the worst case). The orange color wash contour represents the
PTV, the dark blue color wash represents the electron bolus.
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FIG. 7.
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DVHs for two PMRT patients comparing PTV (red), lungs (blue), heart (magenta), and
contralateral breast (green) for mixed beam therapy (dashed line) and VMAT (solid line).
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The PTV volume, minimum (min) distance between the distal PTV surface and lung (dPTV-Lung), volume of
tissue between the distal PTV surface and heart or lung (VPTV-heart/lung), the electron energy used in mixed
beam therapy for each patient.

Author Manuscript

Patient

PTV volume (cm3)

Min dPTV-Lung (cm)

VPTV-heart/Lung (cm3)

Electron energy (MeV)

CW1

991.0

0.5

292.4

13

CW2

749.4

0.7

293.7

11

CW3

700.0

0.4

255.5

11

CW4

1321.3

1.0

585.8

16

CW5

1137.6

0.2

323.2

11

CW6

724.4

0.2

169.9

11

CW7

894.1

0.5

210.3

13

CW8

572.6

0.4

188.9

11

CW9

999.8

0.5

287.8

13
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Starting VMAT optimization objectives and constraints. Min: minimum; Max: maximum; DVH: dose volume
histogram. Dashed table entry indicates the value does not apply to that type of objective.
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ROI

Type

Target Dose [cGy]

Volume [%]

Weight

PTV evaluation

Min DVH

5000

98

100

PTV evaluation

Max Dose

5200

-

100

Total Lung

Max DVH

1500

15

1

Total Lung

Max DVH

1000

35

1

Total Lung

Max DVH

500

60

1

Total Lung

Max Dose

4500

-

1

Heart

Max DVH

1500

15

1

Heart

Max DVH

1000

30

1

Heart

Max Dose

4000

-

1

Esophagus

Max Dose

2000

-

1

Airway

Max Dose

2000

-

1

Spinal Cord

Max Dose

1000

-

1

Contralateral Breast

Max Dose

1500

-

1

Unspecified Tissue

Max Dose

2800

-

1
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Mixed beam

VMAT

0.6
0.5
0.6
0.5
0.6

CW5

CW6

CW7

CW8

CW9

0.7

CW9

0.4

0.7

CW8

0.5

0.8

CW7

CW4

0.7

CW6

CW3

0.7

CW5

0.5

0.7

CW4

0.6

0.6

CW3

CW2

0.7

CW2

CW1

0.7

CI

CW1

Patient

Med Phys. Author manuscript; available in PMC 2019 July 01.
0.2

0.2

0.2

0.2

0.2

0.2

0.2

0.2

0.2

0.1

0.1

0.1

0.1

0.2

0.1

0.1

0.1

0.2

DHI

PTV

2.8

3.2

3.0

3.2

2.6

2.3

2.6

1.7

2.4

2.4

2.4

2.7

3.4

2.6

3.0

2.8

2.7

2.7

Lung

0.1

0.1

0.7

0.7

0.1

0.02

0.1

0.1

0.1

0.5

0.6

0.5

1.6

1.7

0.3

0.3

1.0

0.7

Heart

NTCP (%)

15.0

16.2

15.8

16.1

14.4

13.4

14.3

11.2

13.9

13.7

13.8

14.6

16.8

14.4

15.7

15.1

14.7

14.9

Lung

LNT

2.3

1.2

1.5

2.2

1.3

2.4

1.9

1.1

1.3

3.9

3.2

2.5

3.7

1.9

3.2

4.6

2.1

3.0

CL breast

3.7

3.2

3.9

3.9

4.0

4.5

4.0

3.6

3.9

4.4

4.4

5.0

4.8

4.2

4.7

4.6

4.3

4.6

Lung

LEXP

SCCP (%)

1.4

1.0

1.1

1.3

1.1

1.5

1.4

0.9

1.0

2.2

1.9

1.6

2.2

1.4

2.0

2.4

1.5

2.0

CL breast

PTV and OAR evaluation metrics for each PMRT patient. LNT: linear non-threshold; LEXP: linear-exponential; CL breast: contralateral breast.
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Table IV
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PTV and OAR evaluation metrics (mean ± standard deviation) for a set of 9 PMRT patients and p value for
statistical significance tests. LNT: linear non-threshold; LEXP: linear-exponential; CL breast: contralateral
breast; NS: not significant.
Mixed beam

VMAT

p

Dmean (Gy)

51.6 ± 0.4

49.7 ± 0.3

<0.001

Dmax (Gy)

59.9 ± 3.6

53.5 ± 0.7

<0.001

V107 (%)

15.0 ± 8.6

0.03 ± 0.05

<0.001

CI

0.53 ± 0.06

0.70 ± 0.04

<0.001

DHI

0.20 ± 0.02

0.12 ± 0.02

<0.001

Dmean (Gy)

8.4 ± 0.9

8.7 ± 0.6

NS

Dmax (Gy)

52.0 ± 2.2

51.1 ± 1.6

0.006

V5

33.5 ± 2.6

43.5 ± 5.8

<0.001

V10

23.4 ± 2.9

24.3 ± 2.4

NS

V20

15.5 ± 2.6

13.0 ± 1.0

0.02

NTCP (%)

2.7 ± 0.5

2.7 ± 0.3

NS

SCCP (LNT) (%)

14.5 ± 1.6

14.9 ± 1.0

NS

SCCP (LEXP) (%)

3.9 ± 0.4

4.6 ± 0.3

<0.001

Dmean (Gy)

7.1 ± 1.3

9.3 ± 1.1

0.001

Dmax (Gy)

38.9 ± 4.6

42.8 ± 3.6

NS

V5

44.3 ± 7.6

66.9 ± 13.0

<0.001

V10

21.0 ± 5.7

25.3 ± 4.1

NS

V22.5

4.5 ± 3.4

9.8 ± 1.9

0.001

V30

1.3 ± 1.8

5.0 ± 2.6

0.003

NTCP (%)

0.23 ± 0.27

0.80 ± 0.53

0.01

Dmean (Gy)

1.8 ± 0.6

4.0 ± 1.1

<0.001

Dmax (Gy)

26.6 ± 7.7

27.1 ± 8.4

NS

V5

4.6 ± 3.2

24.2 ± 12.1

<0.001

SCCP (LNT) (%)

1.7 ± 0.5

3.1 ± 0.9

<0.001

SCCP (LEXP) (%)

1.2 ± 0.2

1.9 ± 0.3

<0.001

Dmean (Gy)

50.8 ± 0.5

49.3 ± 0.4

<0.001

Dmax (Gy)

59.7 ± 1.6

53.3 ± 0.7

<0.001

PTV

Lung
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Heart

Author Manuscript

CL breast

Author Manuscript

Skin
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